Inflammatory arthritis that developed following immune checkpoint inhibitor (ICI) therapy for cancer persisted for several months following cessation of ICI therapy and necessitated management by a rheumatologist. At 6 months follow-up, 20 out of 41 patients for whom data were available had active inflammatory arthritis. Overall, three-quarters of the 60 patients included in the follow-up study required immunosuppressive treatment for their inflammatory arthritis, which did not seem to affect cancer progression.
References
Original article
Braaten, T. J. et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-216109 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Checkpoint inhibitor-induced arthritis is persistent. Nat Rev Rheumatol 15, 698 (2019). https://doi.org/10.1038/s41584-019-0329-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0329-0